Physician profile
Muneeza Muhammad
NPI 1578982203
$16,523.74
in general payments reported to CMS, 2019-2025
30 companies · $3,739 in 2025
The $3,739 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $231 · 2021: $593 · 2022: $3,303 · 2023: $3,670 · 2024: $3,999 · 2025: $3,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,109.18 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,035.85 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $2,034.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,586.71 | 2021-2025 | |
| Revance Therapeutics, INC. | $1,384.72 | 2024-2025 | Daxxify, Daxi |
| Regeneron Healthcare Solutions, INC. | $1,253.17 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,219.74 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $896.60 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $765.29 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $709.97 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $647.44 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $603.83 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $577.62 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $337.67 | 2022-2024 | Sotyktu, Sprycel |
| Pfizer INC. | $333.14 | 2019-2025 | |
| Amgen INC. | $288.07 | 2022-2025 | Otezla, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $269.90 | 2023-2025 | |
| Ucb, INC. | $201.24 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $180.91 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $152.42 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Almirall LLC | $150.61 | 2023-2025 | Seysara |
| Merz North America, INC. | $145.96 | 2024 | |
| Allergan, INC. | $135.55 | 2019 | |
| Organon LLC | $127.01 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $121.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Journey Medical Corporation | $93.10 | 2022-2025 | |
| Botanix Sb INC | $87.19 | 2025 | Sofdra |
| Epi Health, LLC | $48.31 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $20.58 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneeza Muhammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.